Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London

Pharming Group announced its participation in the 2026 Jefferies Global Healthcare Conference on November 16-19, with management presenting on November 18. The company reported strong revenue growth in Q3 2026 and highlighted the MHRA approval of Joenja® (leniolisib) as the first treatment specifically for children with APDS in the U.K., along with upcoming CVID topline data expected in November.

11/11/2026, 2:00 AM • GlobeNewswire

MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.

The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has approved an extension of Pharming's Joenja® (leniolisib) to treat children aged 4 to 11 years weighing at least 27kg with activated PI3K delta syndrome (APDS), a rare primary immunodeficiency. This marks the first treatment approved in the U.K. specifically for children with APDS, with availability expected in February 2027. The approval is supported by clinical data from Pharming's pediatric clinical program.

11/06/2026, 1:00 AM • GlobeNewswire

Pharming: 3 Key Takeaways for Long-Term Investors

Pharming reported Q3 2026 revenue growth of 21% to $117.6 million with operating profit surging 89% to $29.9 million. The company's core rare disease product RUCONEST stabilized demand, while Joenja accelerated 58% growth through geographic and pediatric expansion. Management is advancing its clinical pipeline into larger immunodeficiency markets with $191 million in cash and no need for external financing.

11/04/2026, 5:00 PM • The Motley Fool

Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026

Pharming Group reported Q1 2026 revenues of US$72.4 million (8% decrease YoY), with RUCONEST® declining 15% due to anticipated inventory drawdowns and market exit, while Joenja® grew 34% YoY. The company resubmitted pediatric sNDA to FDA for Joenja® and received positive CHMP opinion for European approval. Pharming maintained 2026 revenue guidance of US$405-425 million and generated positive operating cash flow of US$2.0 million.

05/07/2026, 1:00 AM • GlobeNewswire

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

Pharming Group N.V. will report its preliminary Q1 2026 financial results and provide a business update on May 7, 2026, with a conference call and webcast for analysts and investors. The company will also hold its 2026 Annual General Meeting of Shareholders on May 28, 2026.

04/23/2026, 2:00 AM • GlobeNewswire

Pharming Group to participate in April investor conferences

Pharming Group N.V. announced its participation in investor conferences in April 2026, including the Needham Virtual Healthcare Conference and Van Lanschot Kempen Life Sciences Conference. The company also announced a positive CHMP (Committee for Medicinal Products for Human Use) opinion for Joenja® (leniolisib) for treating APDS in adult and pediatric patients 12 years and older, and filed its 2025 Annual Report on Form 20-F.

04/07/2026, 2:00 AM • GlobeNewswire

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

Pharming Group announced that Japan's Ministry of Health, Labour and Welfare has approved Joenja® (leniolisib) for treating APDS in patients aged 4 years and older. This marks the first approved treatment for APDS in Japan and the first global approval for children aged 4-11 with the disease. The approval was based on positive Phase III clinical trial data showing significant improvements in lymphadenopathy reduction and naïve B cell percentage.

03/24/2026, 2:00 AM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

Pomerantz Law Firm is investigating Pharming Group N.V. for potential securities fraud following the FDA's issuance of a Complete Response Letter rejecting the company's supplemental application for Joenja® (leniolisib) for pediatric patients. The FDA cited concerns about drug underexposure in lower weight patients and analytical method issues. The news triggered a 17.07% stock price decline on February 2, 2026.

02/24/2026, 4:50 PM • GlobeNewswire

Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS

Pharming Group received a Complete Response Letter from the FDA for its supplemental application to expand Joenja® (leniolisib) to children aged 4-11 with APDS. The FDA requested additional pediatric pharmacokinetic data to address concerns about potential underexposure in lower weight patients and clarification on analytical batch testing methods. Pharming plans to work with the FDA to address these issues and request a Type A meeting for resubmission. The existing approval for patients 12 years and older remains unaffected.

02/01/2026, 3:17 PM • GlobeNewswire

Pharming Group appoints Kenneth Lynard as Chief Financial Officer

Pharming Group N.V. announced the appointment of Kenneth Lynard as Chief Financial Officer, effective October 1, 2025. Lynard brings over 20 years of global finance leadership experience in life sciences, previously serving as CFO at Schoeller Allibert, Zentiva, and holding senior roles at Gilead Sciences.

09/02/2025, 1:00 AM • GlobeNewswire